文献速递泌尿生殖腹部MRUS

靶向MRI/超声融合引导活检漏诊临床显著前列腺癌的原因分析

Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy.
PubMed 文献 · Eur J Radiol · 2021-02-10

本研究纳入2014年1月至2019年4月连续785例接受3T多参数前列腺MRI及后续MRI/超声融合引导靶向活检联合12针系统活检的患者,分析靶向活检漏诊而系统活检检出的临床显著前列腺癌病例。342例患者有临床显著前列腺癌,其中42例(13%)仅由系统活检检出,主要漏诊原因为MRI分割不足或病灶配准不精确。

要点

  • 靶向活检漏诊临床显著前列腺癌的病例中,48%存在病灶配准不足,31%存在MRI分割不足。
  • 系统活检额外检出临床显著前列腺癌的获益在PSAD≤0.15 ng/mL/cm³的男性中有限。
  • 靶向活检漏诊的临床显著前列腺癌中,36例阳性系统活检针位置与mpMRI可疑区域匹配。

关键影像表现/征象

  • 靶向活检漏诊的临床显著前列腺癌病例中,36例阳性系统活检针位置与mpMRI描述的可疑区域匹配。
  • 靶向活检漏诊的临床显著前列腺癌原因包括:MRI分割不足(前列腺边界相关性)31%和/或病灶配准不足(病灶转移、追踪和/或匹配)48%、遗漏小病灶14%、大病灶中心失败10%。

诊断标准与关键数值

  • 临床显著前列腺癌患者342例,中位PSAD为0.29 ng/mL/cm³;系统活检检出的非显著前列腺癌患者中位PSAD为0.15 ng/mL/cm³。
  • 42例(13%)临床显著前列腺癌仅由系统活检检出。

临床应用与阅片要点

  • 阅片及活检时应验证MRI质量、精确评估mpMRI可疑区域、提高活检经验,可能改善靶向活检准确性。
  • 对于PSAD≤0.15 ng/mL/cm³的男性,额外系统活检增加的临床获益有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study evaluates cases with clinically significant prostate cancer (csPCa) missed by targeted biopsy (TB) and analyzes the diagnostic impact of an additional systematic biopsy (SB) in a large patient collective.

METHODS: Consecutive patients with a 3 T multiparametric prostate MRI (mpMRI) and a subsequent MRI/US fusion-guided TB plus 12-core US-guided SB from 01/2014 to 04/2019 were included in this study. Primary study endpoint was the analysis of cases with a csPCa missed by TB and detected by SB. Secondary study objectives were the PCa detection and the correlation with clinical and MRI parameters.

RESULTS: In total 785 patients met the inclusion criteria. 342 patients had a csPCa (median PSAD 0.29 ng/mL/cm3). In 42 patients (13 %), a csPCa was detected only by SB. In 36 of these cases, the localization of the positive SB cores matched with the cancer suspicious region described on mpMRI (mCSR). Cases with a csPCA missed by TB showed either an insufficient MRI segmentation (prostate boundary correlation) (31 %) and/or insufficient lesion registration (lesion transfer, tracking, and/or matching) (48 %), a missed small lesion (14 %), or a failed center of a large lesion (10 %). Median PSAD of patients with non-significant PCa detected by SB was 0.15 ng/mL/cm3.

CONCLUSIONS: Main reasons for missing a csPCa by TB were insufficient prostate segmentation or imprecise lesion registration within MRI/US fusion-guided biopsy. Consequently, verification of MRI quality, exact mCSR assessment, and advanced biopsy experience may improve accuracy. Altogether, an additional SB adds limited clinical benefit in men with PSAD ≤ 0.15 ng/mL/cm3.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Klingebiel M, Arsov C, Ullrich T, et al. Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy. Eur J Radiol. 2021. PMID: 33592552. doi:10.1016/j.ejrad.2021.109587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。